Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden.
J Exp Med. 2013 Aug 26;210(9):1729-42. doi: 10.1084/jem.20122842. Epub 2013 Aug 19.
DNA repair mechanisms are fundamental for B cell development, which relies on the somatic diversification of the immunoglobulin genes by V(D)J recombination, somatic hypermutation, and class switch recombination. Their failure is postulated to promote genomic instability and malignant transformation in B cells. By performing targeted sequencing of 73 key DNA repair genes in 29 B cell lymphoma samples, somatic and germline mutations were identified in various DNA repair pathways, mainly in diffuse large B cell lymphomas (DLBCLs). Mutations in mismatch repair genes (EXO1, MSH2, and MSH6) were associated with microsatellite instability, increased number of somatic insertions/deletions, and altered mutation signatures in tumors. Somatic mutations in nonhomologous end-joining (NHEJ) genes (DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80, and XRCC6/KU70) were identified in four DLBCL tumors and cytogenetic analyses revealed that translocations involving the immunoglobulin-heavy chain locus occurred exclusively in NHEJ-mutated samples. The novel mutation targets, CHEK2 and PARP1, were further screened in expanded DLBCL cohorts, and somatic as well as novel and rare germline mutations were identified in 8 and 5% of analyzed tumors, respectively. By correlating defects in a subset of DNA damage response and repair genes with genomic instability events in tumors, we propose that these genes play a role in DLBCL lymphomagenesis.
DNA 修复机制对于 B 细胞的发育至关重要,B 细胞的发育依赖于免疫球蛋白基因的体细胞多样化,包括 V(D)J 重组、体细胞高频突变和类别转换重组。这些机制的失败被认为会促进 B 细胞中的基因组不稳定性和恶性转化。通过对 29 个 B 细胞淋巴瘤样本中的 73 个关键 DNA 修复基因进行靶向测序,我们在各种 DNA 修复途径中发现了体细胞和种系突变,主要发生在弥漫性大 B 细胞淋巴瘤 (DLBCL) 中。错配修复基因 (EXO1、MSH2 和 MSH6) 的突变与微卫星不稳定性、体细胞插入/缺失数量增加以及肿瘤中突变特征的改变有关。非同源末端连接 (NHEJ) 基因 (DCLRE1C/ARTEMIS、PRKDC/DNA-PKcs、XRCC5/KU80 和 XRCC6/KU70) 的体细胞突变发生在 4 个 DLBCL 肿瘤中,细胞遗传学分析显示涉及免疫球蛋白重链基因座的易位仅发生在 NHEJ 突变的样本中。我们进一步在扩展的 DLBCL 队列中筛选了 CHEK2 和 PARP1 这两个新的突变靶点,并在 8%和 5%的分析肿瘤中分别发现了体细胞突变以及新的和罕见的种系突变。通过将 DNA 损伤反应和修复基因的缺陷与肿瘤中的基因组不稳定性事件相关联,我们提出这些基因在 DLBCL 肿瘤发生中发挥作用。